Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Carcinoma, Intraductal, Noninfiltrating
Interventions: DRUG: Pembrolizumab|BIOLOGICAL: Intralesional mRNA 2752
Sponsor: Laura Esserman
Collaborators: Merck Sharp & Dohme LLC|ModernaTX, Inc.